Rezolute, Inc.

NasdaqCM:RZLT Stock Report

Market Cap: US$257.3m

Rezolute Management

Management criteria checks 3/4

Rezolute's CEO is Nevan Elam, appointed in Jan 2013, has a tenure of 11.92 years. total yearly compensation is $1.19M, comprised of 46.1% salary and 53.9% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $34.71K. The average tenure of the management team and the board of directors is 2.9 years and 4.3 years respectively.

Key information

Nevan Elam

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage46.1%
CEO tenure11.9yrs
CEO ownership0.01%
Management average tenure2.9yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21
Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Jul 25
Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Jan 31
We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute GAAP EPS of -$0.37

Sep 15

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

May 06
We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute shares rise on positive topline results from RZ402 eye disease trial

May 04

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12
What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

CEO Compensation Analysis

How has Nevan Elam's remuneration changed compared to Rezolute's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$69m

Jun 30 2024US$1mUS$550k

-US$68m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023n/an/a

-US$57m

Sep 30 2023n/an/a

-US$56m

Jun 30 2023US$974kUS$534k

-US$52m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022US$8mUS$515k

-US$41m

Mar 31 2022n/an/a

-US$38m

Dec 31 2021n/an/a

-US$31m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021US$5mUS$496k

-US$21m

Mar 31 2021n/an/a

-US$18m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020US$4mUS$490k

-US$20m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019n/an/a

-US$37m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019US$732kUS$453k

-US$33m

Mar 31 2019n/an/a

-US$42m

Dec 31 2018n/an/a

-US$25m

Sep 30 2018n/an/a

-US$27m

Jun 30 2018US$468kUS$450k

-US$30m

Compensation vs Market: Nevan's total compensation ($USD1.19M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Nevan's compensation has increased whilst the company is unprofitable.

CEO

Nevan Elam (57 yo)

11.9yrs

Tenure

US$1,192,700

Compensation

Mr. Nevan Charles Elam, J.D., is a Founder of Rezolute, Inc. and serves as its Chief Executive Officer and Director at since January 31, 2013. Mr. Elam serves as Acting Chairman of the Board at Rezolute, I...

Leadership Team

NamePositionTenureCompensationOwnership
Nevan Elam
Founder11.9yrsUS$1.19m0.013%
$ 34.7k
Daron Evans
Chief Financial Officerless than a yearUS$384.07k0.32%
$ 812.1k
Brian Roberts
Chief Medical Officer4.9yrsUS$817.96k0.12%
$ 305.1k
Davelyn Hood
Director and Head of Scientific & Patient Affairs3.6yrsno datano data
Michael Deperro
Senior VP & Head of Corporate Development1.9yrsno datano data
Michael Covarrubias
Senior VP & Head of Program & Portfolio Management3.8yrsno datano data
Chris Milks
VP & Head of Financeno datano datano data
Raj Agrawal
VP & Head of Ophthalmological Clinical Developmentno datano datano data
Robyn Sweinhart
VP & Head of Qualityno datano datano data
Erin O'Boyle
Senior VP & Head of Clinical Operationsno datano datano data
Susan Stewart
Chief Regulatory Officer2.2yrsno datano data
Gopal Saha
Senior Vice President of Global Clinical Developmentless than a yearno datano data

2.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: RZLT's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nevan Elam
Founder11.9yrsUS$1.19m0.013%
$ 34.7k
Jerrold Olefsky
Member of the Scientific Advisory Board10.7yrsno datano data
Gilbert Labrucherie
Independent Director5.1yrsUS$93.44k0.098%
$ 251.2k
Philippe Fauchet
Independent Director4.3yrsUS$90.44k0%
$ 0
Young-Jin Kim
Director5.8yrsUS$45.00k0.20%
$ 512.6k
Scott Morenstein
Board Observerno datano datano data
Quan Dong Nguyen
Member of the Scientific Advisory Board3.6yrsno datano data
Nerissa Kreher
Independent Director3.8yrsUS$86.44k0%
$ 0
Robert B. Bhisitkul
Member of the Scientific Advisory Boardno datano datano data
Wladimir Hogenhuis
Independent Director3.8yrsUS$93.44k0.072%
$ 185.4k
Adrian Vella
Member of the Scientific Advisory Board3.3yrsno datano data
So-Hyun Kwon
Board Observerno datano datano data

4.3yrs

Average Tenure

57yo

Average Age

Experienced Board: RZLT's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:29
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Edward NashCanaccord Genuity
Pete StavropoulosCantor Fitzgerald & Co.